NCT00073203已完成2 期
A 6- Week, Randomized, Double-Blind, Parallel-Group, Active-and Placebo-Controlled Trial to Assess the Efficacy of R228060 in Adult Subjects With Major Depressive Disorder (MDD)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.2 个研究点 分布在 1 个国家目标入组 488 人开始时间: 2003年11月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 488
- 试验地点
- 2
研究概览
简要总结
The purpose of this research study is to determine the effectiveness of 2 target doses of R228060 in comparison with placebo during 6 weeks of treatment in moderately to severely depressed adult subjects with major depressive disorder.
Approximately 488 subjects will be involved in the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid ArthritisArthritis, RheumatoidNCT00413660Pfizer509
已完成
2 期
RN624 For Pain Of Post-Herpetic NeuralgiaNeuralgia, PostherpeticNCT00568321Pfizer99
已完成
2 期
Study to Determine the Efficacy, Safety, Tolerability & Pharmacokinetics of RO 205-2349 in Patients With Type 2 Diabetes MellitusDiabetesNCT00057304Hoffmann-La Roche190
已完成
3 期
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative ColitisUlcerative ColitisNCT00073021Warner Chilcott386
已完成
2 期
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisPsoriasisNCT00678210Pfizer197